Drugs / Vitalangio1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07618351 | Jun 2023 → Jan 2025 | thrombotic disease | Peking University First Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vitalangio1 | “The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a new drug, Vitalangio1, in healthy male and female...” NCT07618351 ↗ |
| Route | Oral | “Receive either Vitalangio1 tablets or a placebo orally (through single or multiple escalating doses).” NCT07618351 ↗ |